Sort
39,280 grants matching “leukemia”
NCTN Lead Academic Participating Site at Dana-Farber/Partners Cancer Care
$1,048,779Harold John Burstein · Dana-Farber Cancer Inst · UG1 · FY2025 · CA
NCTN Lead Academic Participating Site at Dana-Farber/Partners Cancer Care
$1,048,778Harold John Burstein · Dana-Farber Cancer Inst · UG1 · FY2024 · CA
Hematopathology Diagnosis
$1,048,728Elaine Jaffe · Division Of Basic Sciences - Nci · ZIA · FY2024 · CA
Mouse Models of Myeloid Leukemia
$1,048,411Kevin M Shannon · University Of California, San Francisco · U01 · FY2007 · CA
Genetic Aspects Of Viral Oncogenesis In Inbred Strains and Wild Mouse Species
$1,047,797Christine Kozak · National Institute Of Allergy And Infectious Diseases · ZIA · FY2017 · AI
TET enzymes as guardians of genome stability
$1,047,600Anjana Rao · La Jolla Institute For Immunology · R35 · FY2019 · CA
MolecularCellular Regulation of Hematopoiesis
$1,047,533Jonathan R Keller · Division Of Basic Sciences - Nci · Z01 · FY2008 · CA
Integrating Transforming Approaches to Identify and Target New Vulnerabilities in Cancer
$1,046,441Kimberly Stegmaier · Dana-Farber Cancer Inst · R35 · FY2017 · CA
Mechanisms and Vulnerabilities of Aberrant Transcriptional Enhancers in Cancer
$1,046,441A Thomas Look · Dana-Farber Cancer Inst · R35 · FY2018 · CA
Mechanisms and Vulnerabilities of Aberrant Transcriptional Enhancers in Cancer
$1,046,441A Thomas Look · Dana-Farber Cancer Inst · R35 · FY2021 · CA
Mechanisms and Vulnerabilities of Aberrant Transcriptional Enhancers in Cancer
$1,046,441A Thomas Look · Dana-Farber Cancer Inst · R35 · FY2016 · CA
Integrating Transforming Approaches to Identify and Target New Vulnerabilities in Cancer
$1,046,441Kimberly Stegmaier · Dana-Farber Cancer Inst · R35 · FY2018 · CA
Integrating Transforming Approaches to Identify and Target New Vulnerabilities in Cancer
$1,046,441Kimberly Stegmaier · Dana-Farber Cancer Inst · R35 · FY2021 · CA
Integrating Transforming Approaches to Identify and Target New Vulnerabilities in Cancer
$1,046,441Kimberly Stegmaier · Dana-Farber Cancer Inst · R35 · FY2016 · CA
Mechanisms and Vulnerabilities of Aberrant Transcriptional Enhancers in Cancer
$1,046,441A Thomas Look · Dana-Farber Cancer Inst · R35 · FY2017 · CA
Mechanisms and Vulnerabilities of Aberrant Transcriptional Enhancers in Cancer
$1,046,441A Thomas Look · Dana-Farber Cancer Inst · R35 · FY2020 · CA
Mechanisms of axon guidance during development
$1,046,341Edward Giniger · National Institute Of Neurological Disorders And Stroke · Z01 · FY2008 · NS
Developing Immune Based Therapies
$1,045,977Crystal Mackall · Division Of Basic Sciences - Nci · ZIA · FY2009 · CA
Tissue Bank
$1,045,937Rona S Weinberg · Icahn School Of Medicine At Mount Sinai · P01 · FY2007 · CA
Innovation through collaboration at the intersection of childhood development and cancer: a platform for the Gabriella Miller Kids First Pediatric DataResource Center
$1,045,732Adam Cain Resnick · Children'S Hosp Of Philadelphia · U2C · FY2019 · HL
ABNORMAL SIGNAL TRANSDUCTION IN HEMATOPOIETIC DISEASE
$1,045,190Dana-Farber Cancer Institute · P01 · FY2001 · DK
Gene Therapy for SCID-X1 using a self-inactivating (SIN) gammaretroviral vector
$1,044,958David A Williams · Boston Children'S Hospital · U01 · FY2011 · AI
Host Defense Regulation and Viral Oncogenesis
$1,044,934Glen N. Barber · University Of Miami School Of Medicine · P01 · FY2013 · CA
OSU as a Network Lead Academic Participating Site for the NCI NCTN
$1,044,921Claire F Verschraegen · Ohio State University · UG1 · FY2025 · CA
Eosinophils and Eosinophil Activation in the Pathogenesis of Human Disease
$1,044,758Amy Klion · National Institute Of Allergy And Infectious Diseases · ZIA · FY2014 · AI